Deacetylation of TFEB promotes fibrillar Aβ degradation by upregulating lysosomal biogenesis in microglia by Jintao Bao et al.
RESEARCH ARTICLE
Deacetylation of TFEB promotes ﬁbrillar Aβ
degradation by upregulating lysosomal
biogenesis in microglia
Jintao Bao1, Liangjun Zheng1, Qi Zhang1, Xinya Li1, Xuefei Zhang1, Zeyang Li1, Xue Bai1, Zhong Zhang1,
Wei Huo1, Xuyang Zhao2, Shujiang Shang3, Qingsong Wang1&, Chen Zhang3&, Jianguo Ji1&
1 State Key Laboratory of Protein and Plant Gene Research, College of Life Sciences, Peking University, Beijing 100871,
China
2 Institute of Systems Biomedicine, Department of Pathology, School of Basic Medical Sciences, Center for Age-Related
Diseases, Peking University Health Science Center, Beijing 100191, China
3 State Key Laboratory of Biomembrane and Membrane Biotechnology, Peking University, Beijing 100871, China
& Correspondence: wangqingsong@pku.edu.cn (Q. Wang), ch.zhang@pku.edu.cn (C. Zhang), jijg@pku.edu.cn (J. Ji)
Received January 26, 2016 Accepted March 21, 2016
ABSTRACT
Microglia play a pivotal role in clearance of Aβ by
degrading them in lysosomes, countering amyloid pla-
que pathogenesis in Alzheimer’s disease (AD). Recent
evidence suggests that lysosomal dysfunction leads to
insufﬁcient elimination of toxic protein aggregates. We
tested whether enhancing lysosomal function with
transcription factor EB (TFEB), an essential regulator
modulating lysosomal pathways, would promote Aβ
clearance in microglia. Here we show that microglial
expression of TFEB facilitates ﬁbrillar Aβ (fAβ) degra-
dation and reduces deposited amyloid plaques, which
are further enhanced by deacetylation of TFEB. Using
mass spectrometry analysis, we ﬁrstly conﬁrmed
acetylation as a previously unreported modiﬁcation of
TFEB and found that SIRT1 directly interacted with and
deacetylated TFEB at lysine residue 116. Subsequently,
SIRT1 overexpression enhanced lysosomal function
and fAβ degradation by upregulating transcriptional
levels of TFEB downstream targets, which could be
inhibited when TFEB was knocked down. Furthermore,
overexpression of deacetylated TFEB at K116R mutant
in microglia accelerated intracellular fAβ degradation by
stimulating lysosomal biogenesis and greatly reduced
the deposited amyloid plaques in the brain slices of
APP/PS1 transgenic mice. Our ﬁndings reveal that
deacetylation of TFEB could regulate lysosomal bio-
genesis and fAβ degradation, making microglial activa-
tion of TFEB a possible strategy for attenuating amyloid
plaque deposition in AD.
KEYWORDS Alzheimer’s disease, microglia,
lysosomes, TFEB, SIRT1, deacetylation
INTRODUCTION
The most common form of Alzheimer’s disease (AD)
appears sporadically during the aging process and is char-
acterized by deposition of β-amyloid (Aβ) peptides within the
brain. An imbalance between Aβ clearance and production
results in its accumulation as amyloid plaques that usually
lead to perturbations of neural network (Palop and Mucke,
2010; Querfurth and LaFerla, 2010). Recent studies indi-
cated that the inefﬁcient Aβ removal might be the signiﬁcant
underlying mechanism in sporadic AD (Mawuenyega et al.,
2010). Therefore, how to stimulate Aβ degradation within the
brain needs to be thoroughly investigated.
Microglia, the resident macrophages in the central ner-
vous system (CNS), play a key role in surveying the brain for
abnormalities and are quickly activated in response to cer-
tain stimuli such as cellular debris or misfolded proteins
(Lucin and Wyss-Coray, 2009; Nimmerjahn et al., 2005).
Previous studies indicated that microglia were recruited to
and activated by amyloid plaque mainly containing ﬁbrillar
Aβ, which is the clinical hallmark of AD in advanced stage
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(Meyer-Luehmann et al., 2008; Rogers et al., 2002). More-
over, inhibition of microglia accumulation accelerates the
burden of plaques deposition within the brain (El Khoury
et al., 2007). Several lines of evidence showed that microglia
take up and degrade both soluble Aβ (sAβ) and ﬁbrillar Aβ
(fAβ), which contributes to the clearance of Aβ in addition to
extracellular proteolysis pathway (Lucin and Wyss-Coray,
2009). Recent studies revealed that lipidated apoliprotein E
(ApoE) contributes to microglial degradation of sAβ through
neprilysin (NEP), a process that is regulated by PPARγ/
LXRs signalling pathway (Jiang et al., 2008; Mandrekar-
Colucci et al., 2012). Despite these ﬁndings, little is known
about the mechanisms underlying fAβ degradation within
microglia.
Lysosomes are regarded as the critical cellular digestive
compartments that are responsible for degradation and
recycling of a variety of intracellular and extracellular
metabolites, depending on their various soluble acidic
hydrolases. Piles of work on this cellular organelle demon-
strated that numerous lysosomal storage disorders were
triggered by the inheritated deﬁcits of speciﬁc lysosomal
function (Settembre et al., 2013b). Apart from these early-
onset genetic diseases, it is notable that lysosomal dys-
function always leads to various age-related neurodegener-
ative diseases such as Alzheimer’s (AD), Parkinson’s (PD)
and Huntington’s diseases (HD) (Schultz et al., 2011).
Therefore, upregulation of lysosomal biogenesis, especially
in microglia, may exert beneﬁcial effects on attenuating Aβ
pathogenesis in AD.
Transcription factor EB (TFEB) acts as a master regulator
of lysosomal function by inducing over 500 target genes
related with lysosomal biogenesis and autophagy, which is
induced by its translocation from cytoplasm to nucleus under
certain cellular stresses (Sardiello et al., 2009; Settembre
et al., 2011). Further studies revealed that activation of TFEB
meets the cellular needs to protect against the toxicities of
the abnormal aggregates. Researchers discovered that the
neural toxicity from α-synuclein or htt-aggregates could be
markedly ameliorated when TFEB is overexpressed or
pharmacologically activated in PD or HD animal models,
respectively (Decressac et al., 2013; Tsunemi et al., 2012).
Recently, TFEB is suggested to be participated in the Aβ-
induced pathogenesis of AD by regulating lysosomal path-
way (Zhang and Zhao, 2015). Further evidence indicated
that TFEB enhances lysosomal biogenesis in both astro-
cytes and neuron, contributing to increased sAβ clearance
and reduced Aβ generation, respectively (Xiao et al., 2014;
Xiao et al., 2015). Despite these inﬂuential observations,
whether TFEB would function in microglia and the mecha-
nisms underlying TFEB functional pathway, especially its
upstream regulation within nucleus, remain to be elucidated.
Accumulating evidence suggests that protein acetylation
plays a role in regulating lysosome-mediated autophagy
process (Banreti et al., 2013). SIRT1 is the most conserved
member of sirtuins, a family of NAD+-dependent protein
deacetylases, and contributes to deacetylation of multiple
mammalian transcription factors such as p53, FOXOs, and
NF-κB in nucleus, making it a key metabolic regulator
involved in a vast number of cellular processes associated
with age-related diseases including AD (Guarente, 2011;
Herskovits and Guarente, 2014). Previous work indicated
that SIRT1 protects against Aβ toxicity and cognitive deﬁcits
in animal models mainly through inhibiting inﬂammatory
responses in microglia, because overexpression of SIRT1 in
microglia suppresses NF-κB-signaling while the reduced
level of SIRT1 during the aging process of microglia,
upregulates IL-1β expression (Chen et al., 2005; Cho et al.,
2015). Apart from the inﬂammatory perspective, the molec-
ular mechanisms underlying the protective effects of SIRT1
in microglia are still being investigated.
Considering the critical role of TFEB in lysosomal bio-
genesis, we intended to explore whether TFEB would
increase microglial clearance of Aβ and unveil the mecha-
nisms underlying the upstream regulation of TFEB in lyso-
somal biogenesis in microglia.
In this study, we ﬁrstly identify protein acetylation as a
novel post-translational modiﬁcation of TFEB and demon-
strate that TFEB is deacetylated by SIRT1 at K116. More-
over, SIRT1-mediated deacetylation of TFEB facilitates
microglial degradation of fAβ by enhancing lysosomal bio-
genesis. Therefore, we identify the upstream molecular
mechanism by which deacetylation stimulates TFEB induc-
tion of lysosomal biogenesis to enhance microglial degra-
dation of fAβ and reduction of amyloid plaques, suggesting a
novel strategy for treatment of AD.
RESULTS
TFEB enhances microglial degradation of ﬁbrillar Aβ
in lysosomes
To investigate the contribution of microglia in clearance of
ﬁbrillar Aβ (fAβ), the major constituent of amyloid plaque
deposited in AD brains, we ﬁrst incubated fAβ that was
generated and identiﬁed in vitro with BV2 cells and primary
microglia (Ma et al., 2013). Our results revealed that fAβ was
rapidly taken up and trafﬁcked into lysosomes within 30 min
(Fig. 1A–C). As time prolonged, the internalized fAβ level
increased to the peak level at 3 h and then gradually dis-
appeared at 18 h (Fig. 1B). By conducting this set of pre-
liminary experiment, 3 h and 18 h were interpreted as the
time points representing microglial capabilities of fAβ
phagocytosis and degradation, respectively. Indeed, the fAβ
originally added into the media was immediately and thor-
oughly internalized by microglia and little did we observe any
resecretion in the media (Fig. S1A). Interestingly, we con-
ﬁrmed fAβ is exclusively degraded within lysosomes, for the
reason that inhibitors of lysosomes such as chloroquine or
leupeptin remarkably weaken microglial degradation of fAβ
while phosphoramidon, inhibitor of NEP that is reported for
sAβ degradation (Jiang et al., 2008), exerts little impact on
this process (Fig. 1D). TFEB, as a critical transcription factor
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Hilyte 488-fAβ LysoTracker 15 μm
Figure 1. TFEB enhances microglial degradation of ﬁbrillar Aβ in lysosomes. (A and B) Microglia internalize and efﬁciently
degrade ﬁbrillar Aβ. BV2 cells were incubatedwith fAβ (500 nmol/L) at 37°Cand the cells were harvested and lysed at different time points,
followed by detection of intracellular Aβ levels by Western blotting analysis (A). The band intensity was measured in three independent
experiments indicating relative intracellular Aβ levels and the mean ± SEM are shown in (B). (C) Fibrillar Aβ is rapidly trafﬁcked into
lysosomes.Confocal imagingof liveBV2cells30minafter additionofHilyte488-labeled fAβ (500nmol/L) showed localizationof fAβ (Green)
within lysosomes stainedwith LysoTracker (Red). Scale bar, 15 μm. (D) Internalized fAβ is degraded in lysosomes. Primarymicroglia from
wild-type mice were pretreated with DMSO, Phosphoramidon (NEP inhibitor, 10 μmol/L), Chloroquine or Leupeptin (Lysosome inhibitor,
10 μmol/L) for 18 h. The cells were then incubated with fAβ (500 nmol/L) in the presence of DMSO or inhibitors for an additional 18 h. The
band intensity wasmeasured in three independent experiments indicating relative intracellular Aβ levels. (E and G) TFEB overexpression
increases fAβ degradation in microglia. GFP or human TFEB was overexpressed in BV2 cells (E) or primary microglia (G) by lentiviral
system. The cellswere incubatedwith fAβ (500nmol/L) for 3 h or 18handwere harvested for detection of intracellularAβ levels byWestern
blotting analysis. The band intensity was measured in three independent experiments indicating relative intracellular Aβ levels and the
mean ± SEMare shown in the right panel. Two-wayANOVA, comparison between different time points, **P < 0.01; ***P < 0.001. Unpaired
Student’s t-test, comparison against the Fugw3-GFP, #P < 0.05; ###P < 0.001. (F and H) TFEB knockdown inhibits fAβ degradation in
microglia. Scrambleor TFEBsiRNAwasdelivered intoBV2cells (F) or primarymicroglia (H) for 72h. The cellswere treatedas in (EandG).
Two-way ANOVA, comparison between different time points, **P < 0.01; ***P < 0.001. Unpaired Student’s t-test, comparison against the
Scramble, ###P < 0.001.
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regulating lysosomal biogenesis and lysosomal degradative
pathway, is demonstrated to be involved in the pathogenesis
of neurodegenerative diseases. Recent studies revealed
that TFEB could facilitate oligomeric sAβ clearance by
enhancing astrocytic lysosomal biogenesis (Xiao et al.,
2014). To examine whether TFEB has an effect on microglial
degradation of fAβ, we ﬁrst exogenously expressed TFEB in
BV2 cells and primary microglia by using lentiviral system.
We observed less intracellular fAβ remained in the TFEB
infected cells than that in the GFP infected cells at 18 h,
indicating an enhancement of microglial degradation of fAβ.
Meanwhile, microglial phagocytosis remains the same as
intracellular fAβ levels at 3 h are comparable between cells
infected with TFEB or GFP (Fig. 1E and 1G). Consistent with
the gain-of-function data, siRNA speciﬁc knockdown of
TFEB in microglia greatly reduce their capabilities to
degrade fAβ (Fig. 1F and 1H). Intriguingly, we observed that
TFEB has a tendency to translocate into nucleus upon
stimulation of fAβ which is coincided with previous reports
that TFEB will be activated under certain cellular stress
(Figs. 2 and S2A). However, we proved that fAβ stimulation
failed to inhibit mTORC1 activity which was previously
reported to facilitate TFEB nuclear translocation (Fig. S2B),
for the reason that fAβ stimulation could not inhibit the
phorsphorylation status at speciﬁc sites of mTORC1 sub-
strates as compared with the obvious inhibitory effects
induced by mTORC1 inhibitor Torin1. Taken together, these
data demonstrate that TFEB translocates into nucleus by
fAβ stimulation in a mTORC1-independent pathway and
facilitates fAβ degradation in microglia.
TFEB is acetylated at lysine 116
A wide range of acetylated proteins have been identiﬁed
using mass spectrometry, including numerous transcription
factors whose activities are proved to be regulated by
acetylation. To investigate acetylation status of TFEB, Flag-
tagged human TFEB was transiently transfected into human
embryonic kidney (HEK) 293T cells and its acetylation level
was detected by an anti-acetylated lysine antibody. We
observed a presence of acetylation on this exogenously
expressed TFEB when the cells were treated with nicoti-
namide (NAM) that is an inhibitor of sirtuins family as well as
trichostatin A (TSA) which inhibits activity of histone
deacetylase (HDAC) classes I, II, and IV (Fig. 3A). This
result prompted us to explore the potential acetylation sites
on TFEB by the means of mass spectrometry analysis of
TFEB puriﬁed from 293T cells treated with or without NAM
and TSA (Fig. 3B). We repeatly identiﬁed an acetyl-lysine-
containing peptide (FAAHISPAQGSPKPPPAASPGVR) that
is matched with a region containing K116 on immunopre-
cipitated TFEB, in the cells treated with NAM and TSA
(Fig. 3C). By performing sequence alignment of TFEB
homologues from different species, we found that K116 is
highly conserved in evolution (Fig. 3D). To further ascertain
whether K116 site is acetylated, we generated single
acetylation-deﬁcient TFEB mutant (K-to-R mutation) by site-
directed mutagenesis. As we expected, in contrast with wild-
type TFEB (TFEB-WT), acetylation level of K116R mutant
(TFEB-K116R) can no longer be elevated by NAM treatment
(Fig. 3E). These data document that TFEB can be acetylated
at K116 site which has not been previously recognized.
TFEB is a deacetylation substrate of SIRT1
Given the evidence that TFEB can be acetylated at K116 site
and the knowledge that acetylation status is regarded as a
critical mechanism underlying regulation of activities of
numerous transcription factors, we intended to identify the
upstream regulator that targets TFEB. By performing co-
immunoprecipitation (Co-IP) of exogenously expressed












Figure 2. Fibrillar Aβ stimulates TFEB to translocate
into nucleus. (A–E) TFEB translocates into nucleus under
incubation of ﬁbrillar Aβ. Confocal imaging of BV2 cells
incubated with Hilyte488-labeled fAβ (500 nmol/L, Green)
at different time points and immunostained for endogenous
TFEB (Red). Scale bar, 15 μm.
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analysis, we detected SIRT1 as a potential candidate. To
verify this result, we ﬁrst overexpressed TFEB or SIRT1 in
293Tcells and found endogenous SIRT1 (Fig. S3A) or TFEB
(Fig. S3B) in the immunoprecipitates, respectively. Then we
performed endogenous Co-IP with SIRT1 antibody and also
detected TFEB in the immunoprecipitates (Fig. 4A), indicat-
ing that TFEB physically interacts with SIRT1. Next, we
wondered whether SIRT1 could change the acetylation
levels on TFEB. Treating 293T cells with resveratrol, a
chemical activator of SIRT1, resulted in a reduction of
acetylation on the immunoprecipitated TFEB, while its
acetylation level was augmented by NAM treatment
(Fig. S3C). In addition, the acetylation level on Flag-tagged
TFEB was much lower in cells coexpressing wild-type SIRT1
(SIRT1-WT) than in cells expressing a catalytically inactive
mutant SIRT1 (SIRT1-HY) (Fig. 4B). In parallel with these
results, cells deﬁcient of SIRT1 by knocking down with
speciﬁc siRNA exhibited a higher level of acetylation on
exogenously expressed TFEB-WT, but its deacetylation
mimic TFEB-K116R counteracted SIRT1 knockdown effects,
indicating K116 would be the site deacetylated by SIRT1
(Fig. 4C). To further ascertain whether TFEB is a substrate of
SIRT1, we carried out in vitro deacetylation assay with
puriﬁed SIRT1 and acetylated Flag-tagged TFEB (Fig. S3E).
The data showed that SIRT1-WT, but not the catalytically
inactive mutant SIRT1-HY, deacetylates TFEB in a NAD+-
dependent manner, while treatment with SIRT1 inhibitor
NAM reversed the effect of SIRT1 on TFEB (Fig. 4D).
Despite these intriguing data, we intended to examine
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Figure 3. TFEB is acetylated at lysine 116. (A) Exogenous expressed TFEB is acetylated. Empty vector or Flag-tagged TFEB was
transfected into HEK293Tcells for 24 h treated with sirtuins inhibitor NAM (10 mmol/L) and HDAC I, II, and IV inhibitor TSA (0.5 μmol/L)
and was immunoprecipitated for acetylation Western blotting analysis with the antibody against acetylated lysine. (B) Immunopre-
cipitated Flag-tagged TFEB for mass spectrometry analysis. Flagged-tagged TFEBwas transfected into HEK293Tcells for 24 h treated
with or without NAM (10 mmol/L) and TSA (0.5 μmol/L) and was immunoprecipitated with anti-ﬂag afﬁnity agrose beads, followed by
Commassie Blue R250 staining. (C) Identiﬁcation of TFEB K116 acetylation using mass spectrometry analysis. Flagged-tagged TFEB
was puriﬁed as depicted in (B) and then analyzed using mass spectrometry. (D) Alignment of the protein sequences of TFEB
homologues in different species. The blue mark indicates the identiﬁed acetylated lysine residues of TFEB. (E) Deacetylation mimic of
TFEB (K116R) counteracts NAM acetylation effects on TFEB. Flag-tagged TFEB (WTor K116R) were transfected into HEK293Tcells
for 24 h with or without additional 12 h treatment of NAM (10 mmol/L). Values were expressed as fold changes relative to TFEB-WT
without NAM treatment and normalized to IP-Flag.
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TFEB by using deacetylase inhibitors NAM and TSA. SIRT1
inhibitor NAM exerted a greater impact on increases of
acetylation status of TFEB than HDACI/II/IV inhibitors TSA,
indicating that TFEB is speciﬁcally acetylated by SIRT1
rather than other HDACs (Fig. 4E). Furthermore, SIRT6 and
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Figure 4. TFEB is a deacetylation substrate of SIRT1. (A) TFEB interacts with SIRT1. Endogenous coimmunoprcipitation assay
was conducted with SIRT1 antibody and endogenous TFEB was detected by its speciﬁc antibody. (B) Catalytic activity of SIRT1 is
required for deacetylation of TFEB. Flag-tagged TFEB was co-transfected into HEK293T cells with wild-type SIRT1 (WT) or its
catalytically inactive mutant H363Y (HY), followed by additional treatment with or without NAM before harvest. Acetylation levels of
TFEB were measured by IP Western blotting analysis. Values were expressed as fold changes relative to TFEB-WT without SIRT1
overexpression and normalized to IP-Flag. (C) Deacetylation mimic of TFEB (K116R) counteracts SIRT1 knockdown effects on
acetylation of TFEB. Flag-tagged TFEB (WT or K116R) were co-transfected into HEK293T cells for 24 h with Scramble or SIRT1
siRNA. Acetylation levels of TFEB were measured by IP Western blotting analysis. Values were expressed as fold changes relative to
TFEB-WTwith scramble siRNA transfection and normalized to IP-Flag. (D) In vitro TFEB deacetylation by SIRT1. Puriﬁed Flag-TFEB
and Flag SIRT1 (WT or HY) were co-incubated at 30°C for 6 h treated with or without NAD (5 mmol/L) or NAM (10 mmol/L).
Acetylation levels of puriﬁed Flag-TFEB were measured by Western blotting analysis. Values were expressed as fold changes
relative to TFEB-WTwith NAD treatment and without SIRToverexpression and normalized to puriﬁed Flag-TFEB. (E) NAM, not TSA,
increases TFEB acetylation. Flag-tagged TFEB was transfected into HEK293T cells treated with or without NAM (10 mmol/L) or TSA
(0.5 μmol/L). Acetylation levels of TFEB were measured by IP Western blotting analysis. Values were expressed as fold changes
relative to TFEB-WT without NAM or TSA treatment and normalized to IP-Flag.
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compared with SIRT1 (Fig. S3D), excluding the possibility
that SIRT6 or SIRT7 might involve in deacetylation of TFEB
in the nucleus. Collectively, these ﬁndings demonstrate that
SIRT1 is the primary deacetylase of TFEB in vivo and
in vitro.
SIRT1 accelerates fAβ degradation in microglia
by enhancing lysosomal biogenesis
Based on our evidence that TFEB can be deacetylated by
SIRT1, we hypothesized that SIRT1 may increase lysosomal
biogenesis by activating TFEB, which probably facilitates
fAβ degradation in microglia. For this purpose, we ﬁrst
infected BV2 cells and primary microglia with lentivirally
expressed SIRT1-WT as well as its catalytically inactive
mutant SIRT1-HY. The intracellular Aβ levels reduced more
dramatically after 18-h-incubation with microglia overex-
pressing SIRT1-WT than those overexpressing GFP as a
vector control or SIRT1-HY (Figs. 5A, 5C, and S4A), indi-
cating that only the catalytically active SIRT1 is able to
facilitate microglial degradation of fAβ efﬁciently. Consistent
with this result, siRNA-mediated SIRT1 deﬁciency in micro-
glia attenuated the degradation of fAβ in both BV2 cells and
primary microglia (Figs. 5B and S4B). In addition, pretreating
microglia with resveratrol, the agonist of SIRT1, increased
the clearance of intracellular fAβ in a dose-dependent
manner (Fig. S4C), while SIRT1 inhibitor NAM abolished its
capability to degrade fAβ (Fig. S4D). Meanwhile, we found
that TSA could not affect microglial degradative capability on
fAβ (Fig. S4E), indicating that it is SIRT1, but not other
HDACs, that is responsible for fAβ degradation in microglia.
These results prompted us to further examine whether
SIRT1 could enhance lysosomal biogenesis. In BV2 micro-
glia, we observed an expansion in abundance of lysosomal
compartment stained with LysoTracker Red or lysosome
membrane marker LAMP1 when exogenously transfecting
with GFP-tagged SIRT1-WT, as compared with vector con-
trol or GFP-tagged SIRT1-HY (Fig. 5D). This result is in
accordance with that in HeLa cells (Fig. S6A). The number of
lysosomes, however, decreased in microglia with SIRT1
knockdown (Fig. S4G). Further, we observed microglia pre-
treated with NAM exhibited a diminished lysosomal biogen-
esis compared with the control, while TSA-treated microglia
changed little (Fig. S4F). In addition, qPCR test revealed that
exogenously overexpressed SIRT1-WT is able to stimulate
expression of TFEB downstream targets which are involved
in the process of lysosomal biogenesis as well as lysosome-
mediated degradative pathways (Fig. 5E), while SIRT1
knockdown decreases expression of these genes
(Fig. S4H). Given these evidence, we determined to inves-
tigate whether the function of SIRT1 in fAβ clearance in
microglia depends on its deacetylation on TFEB. Simulta-
neously overexpressing SIRT1 by lentivirus and knocking
down endogenous TFEB neither promote fAβ degradation
nor enrich the abundance of lysosomes in BV2 microglia,
indicating TFEB is required for SIRT1’s effects on facilitating
fAβ degredation and lysosomal biogenesis in microglia
(Fig. 5F and 5G). Collectively, these evidence suggest that
SIRT1 accelerates fAβ degradation by enhancing lysosomal
biogenesis in microglia.
Deacetylation status at K116 of TFEB stimulates fAβ
degradation by facilitating lysosomal biogenesis
Given our previous observations that SIRT1 is the primary
deacetylase of TFEB and its enhancement of fAβ degrada-
tion in microglia counts on TFEB, we determined to explore
the possibility that deacetylated TFEB might increase lyso-
somal function and facilitate fAβ degradation. To address this
question, we infected BV2 microglia with lentivirally overex-
pressed TFEB-WT or TFEB-K116R. The result noted that
K116R mutant displayed a stronger capability in degradation
of fAβ than its wild-type (Fig. 6A), which is accompanied by
observations that more lysosomal compartments were
induced in microglia and HeLa cells transfected with TFEB-
K116R than TFEB-WT (Figs. 6B and S6B). Accordingly,
analysis of these acidic organelles by ﬂuorescence activated
cell sorting (FACS) stained with LysoTracker Red revealed
that there was an expansion of the quantity of lysosomes in
the microglia infected with lentivirally-expressed TFEB-
K116R (Fig. 6C). Furthermore, transcription of TFEB down-
stream targets was signiﬁcantly upregulated in the presence
of TFEB-K116R mutant (Fig. 6D). In order to conﬁrm that the
deacetylated K116R mutant promotes TFEB binding to its
target genes, we performed chromatin immunoprecipitation
(ChIP) assay and found that TFEB-K116R had a much
stronger binding in the promoter of TFEB target gene CLCN7
than the TFEB-WT (Fig. 6E). To further conﬁrm it is the
deacetylation status of TFEB that facilitates fAβ degradation
by upregulating lysosomal function in microglia, we also
evaluated the effects of TFEB-K116Q mutant (acetylation
mimic). The results indicated that microglia with TFEB-
K116Q overexpression could neither facilitate fAβ degrada-
tion (Fig. S5B) nor upregulate the lysosomal biogenesis and
function (Fig. S5C and S5D). Collectively, these data indi-
cate that deacetylation of TFEB intensiﬁes its contribution to
microglial degradation of fAβ.
Microglial expression of deacetylated TFEB reduces
amyloid plaques in brain slices from APP/PS1 mice
To evaluate whether deacetylated TFEB could enhance
microglial degradation of amyloid plaques, we performed
ex vivo brain slice assay as described previously (Bard et al.,
2000), where microglial cells were co-cultured with brain
slices from aged APP/PS1 transgenic mice (Fig. 7A).
Quantitative analysis of thioﬂavine-S staining indicated that
BV2 microglia lentivirally overexpressed with TFEB-K116R
were signiﬁcantly more efﬁcient at clearing the aggregates
deposited in the cortex (Fig. 7B and 7C) and hippocampus
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(Fig. 7D) when compared with its wild-type. In addition,
independent Western blotting measurements of Aβ levels in
the brain slices achieved a similar result (Fig. 7E and 7F).
These ex vivo ﬁndings were consistent with the enhance-
ment of microglial degradation of fAβ in vitro, suggesting a
strengthened capability of microglial removal of Aβ aggre-
gates which is triggered by deacetylation of TFEB. According
to our results, deacetylation of TFEB, carried out by its
deacetylase SIRT1, promotes microglial degradation of fAβ
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biogenesis, which highlights acetylation status of TFEB as a
critical role in the degradative pathway in microglia (Fig. 8).
DISCUSSION
Microglia are the principle immune phagocytic cells in the
CNS which constantly survey their adjacent environment for
maintainance of the homeostasis within the brain. Previous
work revealed that functional deﬁciency in microglia is
associated with much more severe deposition of amyloid
plaques in AD mouse models, indicating a protective role of
microglia in AD (Zhang et al., 2007). Indeed, we and others
have observed that microglia internalize Aβ through mem-
brane receptors and transport them into lysosomes for
degradation (Doens and Fernandez, 2014; Ma et al., 2013).
In this paper, we demonstrated that the ability of microglia to
degrade fAβ could be facilitated by TFEB-mediated upreg-
ulation of intracellular degradative systems.
Several lines of evidence pointed out that the amyloid
deposits cannot be fully eliminated or even remain
stable albeit by surrounding coverage of activated microglia
(Bolmont et al., 2008; Wegiel et al., 2001), which may be
explained in part by the dysfunction of lysosomes in the
presence of Aβ stimulation (Hickman et al., 2008; Majumdar
et al., 2007). Subsequent studies further clariﬁed that
attempts to upregulating intracellular lysosomal hydrolytic
enzymes or stabilizing a ﬁtting lysosomal acidic environment
eventually enhance or restore microglial capability to
degrade Aβ (Majumdar et al., 2011; Majumdar et al., 2008),
which may be suggestive of strengthening lysosomal func-
tion as a novel approach to increase Aβ clearance. In this
regard, our results validated that TFEB, the major regulator
of lysosomal biogenesis, facilitates or rejuvenates microglial
capability in degradation of fAβ and amyloid plaques by
upregulating lysosomal quantity and enhancing lysosomal
function.
Emerging evidence pointed out that defective activation of
TFEB probably underlies aberrant lysosomal function failing
to degrade aggregated toxic proteins in prevalent neurode-
generative diseases (Decressac et al., 2013; Tsunemi et al.,
2012; Xiao et al., 2014). Therefore, appropriate regulation of
TFEB activity has attracted more and more attention in
countering the pathogenesis of these diseases (Settembre
et al., 2013b). Despite the fact that TFEB can be activated by
its own stimulation in a transcriptional autoregulatory path-
way (Settembre et al., 2013a), post-translational modiﬁcation
play an essential role in modulating TFEB activity, among
which phosphorylation is the ﬁrst to be studied. Under basal
conditions, TFEB is mainly sequestered in cytosol where it
remains to be phosphorylated by rapamycin complex
mTORC1 (Settembre et al., 2011). However, once upon
speciﬁc conditions such as starvation or mTOR suppression,
TFEB is rapidly dephosphorylated and translocates into
nucleus for transcriptional activation of lysosomal system, a
process proved to be dependent on autophagosome-lyso-
some fusion (Zhou et al., 2013). Nevertheless, it still remains
a mystery that whether TFEB transcriptional activity needs
proper regulation within the nucleus and could other modi-
ﬁcations be involved in such regulatory mechanisms. In this
regard, for the ﬁrst time, we identiﬁed acetylation as a
prominent post-translational modiﬁcation in regulating TFEB
transcriptional activity within the nucleus. Our results indi-
cated that TFEB translocates into nucleus in a mTORC1-
independent pathway once microglia are under exposure to
fAβ. Although further investigation is needed to unveil the
mechnisms underlying this observation, our ﬁndings suggest
that such translocation may enable TFEB to be deacetylated
by nuclear-located SIRT1, which enhances its transcriptional
Figure 5. SIRT1 accelerates fAβ degradation in microglia
by enhancing lysosomal biogenesis. (A and B) SIRT1
accelerates fAβ degradation in microglia. GFP or human SIRT1
(SIRT1) was overexpressed in BV2 cells by lentiviral system
(A). Scramble or SIRT1 siRNA was delivered into BV2 cells for
72 h (B). Then the cells were incubated with fAβ (500 nmol/L)
for 3 h or 18 h and were harvested for detection of intracellular
Aβ levels by Western blotting analysis. Two-way ANOVA,
comparison between different time points, *P < 0.05; **P < 0.01;
***P < 0.001. Unpaired Student’s t-test, comparison against the
Fugw3-GFP or the Scramble, #P < 0.05, ##P < 0.01. (C) Cat-
alytic activity of SIRT1 is required for degradation of fAβ. GFP
or SIRT1 (WT or H363Y) was overexpressed in BV2 cells by
lentiviral system. The cells were incubated with fAβ (500 nmol/L)
for 18 h and were harvested for detection of intracellular Aβ
levels by Western blotting analysis. One-way ANOVA with
Turkey’s test, comparison against GFP, *P < 0.05. (D) SIRT1
stimulates lysosome biogenesis in microglia. Empty vector or
GFP-tagged SIRT1 (WT or HY) was overexpressed in BV2
cells, followed by staining with an antibody against LAMP1
(Red) or LysoTracker Red, respectively. The ﬂuorescence
signal of each cell was estimated by examining more than 50
cells. One-way ANOVA with Turkey’s test, **P < 0.01; (E) SIRT1
upregulates TFEB induction of its target genes. Quantitative
PCR (qPCR) analysis of TFEB target genes in BV2 cells
overexpressed with empty vector as control or SIRT1 (WT or
HY). Values represent mean ± SEM of three independent
experiments. One-way ANOVA with Turkey’s test, comparison
against CTRL, *P < 0.05; **P < 0.01; ***P < 0.001. (F) TFEB is
required for SIRT1’s effects on accelerating fAβ degradation.
BV2 cells were infected with lentiviral FugW3-GFP or FugW3-
SIRT1 and were simultaneously transfected with scramble or
TFEB siRNA for 72 h. The cells were incubated with fAβ
(500 nmol/L) for an additional 18 h and were harvested for
detection of intracellular Aβ levels by Western blotting analysis.
One-way ANOVA with Turkey’s test, comparison against GFP
with scramble siRNA, **P < 0.01; ***P < 0.001. (G) TFEB is
required for SIRT1’s stimulation of lysosomal biogenesis. BV2
cells were transfected with scramble or TFEB siRNA for 72 h
and were transfected with empty vector or GFP-tagged SIRT1-
WT, followed by staining with an antibody against LAMP1
(Red). The ﬂuorescence signal of each cell was estimated by
examining more than 50 cells. One-way ANOVA with Turkey’s
test, *P < 0.05; ***P < 0.001.
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induction of target genes closely associated with lysosomal
biogenesis, ultimately resulting in a robust degradation of
intracellular fAβ.
Protein acetylation has been recently recognized as a
signiﬁcant approach in controlling autophagic processes
such as elimination of damaged organelles or toxic protein
aggregates (Banreti et al., 2013). Previous studies revealed
that acetylation of ATG proteins, the autophagy core com-
ponents, by acetyltransferase p300 results in autophagy
inhibition (Lee and Finkel, 2009), whereas this effect can be
reversed by NAD+-dependent deacetylase SIRT1 under
particular cellular stresses (Lee et al., 2008). In addition,
SIRT1-mediated deacetylation of FOXO transcription factors
is able to activate autophagy by upregulation of core
autophagy genes in the process of autophagosome forma-
tion (Chakrabarti et al., 2011; Zhao et al., 2007). In the pre-
sent study, we demonstrated that deacetylation of TFEB by
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novel mechanism regulating intracellular degradative path-
ways and validating the importance of protein acetylation in
these processes. However, the exact regulatory role of pro-
tein acetylation in autophagy-lysosome system still needs to
be deﬁned.
SIRT1, the well-studied NAD+-dependent deacetylase,
has been realized as a master regulator of multiple cellular
metabolic processes, including various common neu-
rodegenerative disorders. In particular, AD transgenic
mouse models displayed a strikingly reduced Aβ burden in
the hippocampus and cortex when SIRT1 was chemical
activated or overexpressed by lentiviral infection (Karup-
pagounder et al., 2009). The underlying mechanism was
further explained by observations that neuronal SIRT1
promotes the nonamyloidogenic APP-processing pathway
either by directly enhancing α-secretase activity or by
upregulating expression of α-secretase, respectively
(Donmez et al., 2010; Qin et al., 2006). In contrast with the
knowledge that SIRT1 prevents neuronal Aβ production,
little is known about SIRT1’s function in clearance of Aβ.
Previous studies suggested that SIRT1 in microglia
contributes to amelioration of Aβ-induced inﬂammatory
response by suppressing NF-κB and IL-1β signaling
pathway (Chen et al., 2005; Cho et al., 2015). In this study,
we found that SIRT1 is able to regulate microglial degra-
dation of fAβ. Moreover, we identiﬁed TFEB as a novel
substrate of SIRT1 and provided evidence that SIRT1
upregulates lysosomal biogenesis by stimulating TFEB
induction of its downstream targets, ultimately resulting in
increased fAβ clearance in microglia. However, consider-
ing about the fact that several substrates of SIRT1 were
reported to positively regulate autophagy such as Foxo3
and Atg proteins (Lee and Finkel, 2009; Zhao et al., 2007),
our present data cannot exclude the possibility that SIRT1
may promote fAβ degradation by regulating other mole-
cules in lysosomal-autophagy degradative pathway. Fur-
ther investigation is needed to achieve a better
understanding of the underlying mechanisms of SIRT1-
mediated fAβ degradation. Overall, our ﬁndings uncover a
novel mechanism that SIRT1 protects against Aβ deposits
by facilitating microglial clearance of Aβ other than pre-
venting neuronal production of Aβ.
It is noteworthy that our results are in accordance with a
recent work indicating that TFEB accelerates astrocytic
capability in Aβ removal (Xiao et al., 2014). In fact, these two
glia cells may play distinct roles in Aβ clearance depending
on amyloid aggregation states and pathogenesis stages.
Astrocytes possibly play a constitutive role in the very early
AD stages by taking up oligomeric sAβ, while microglia
mainly function in the late stages as fAβ accumulates to form
ﬁbrillar deposits (Condello et al., 2015; Mulder et al., 2014;
Weldon et al., 1998). In fact, we did conduct the experiment
by culturing sAβ with microglia in our degradative model and
found that deacetylated TFEB could degrade sAβ more
efﬁciently as well (Fig. S5A), which collectively verify the vital
role of deacetylation status of TFEB in Aβ degradation.
Moreover, TFEB overexpression in neuron is recently
reported to reduce Aβ generation by enhancing APP
degradation in lysosomes (Xiao et al., 2015). In this sce-
nario, our results favour a plausible novel therapy that
upregulation of TFEB activities in both glia cells and neuron
may help to coordinately ameliorate AD pathogenesis, pro-
viding a better healing of AD.
In summary, we identify protein acetylation as a novel
mechanism underlying regulation of TFEB transcriptional
activity for the ﬁrst time, and demonstrate that deacetylation
of TFEB in microglia enhances lysosomal biogenesis by
stimulating expression of its target genes, which ultimately
facilitates fAβ degradation and decreased amyloid plaque
deposition. Our ﬁndings highlight that TFEB is a central
regulator in lysosome-mediated clearance of toxic protein
aggregates. Also, distinct post-translational modiﬁcations of
TFEB occurring at different cellular localization may regulate
TFEB activity coordinately in the autophagy-lysosome
pathway. These ﬁndings may provide an appealing avenue
in countering pathogenesis of AD and other neurodegener-
ative diseases.
Figure 6. Deacetylated TFEB facilitates fAβ degradation by
enhancing lysosomal biogenesis. (A) Deacetylation of TFEB
at K116 futher facilitates fAβ degradation. BV2 cells were
infected with lentivirally overexpressed FugW3-GFP or FugW3-
TFEB (WT or K116R). The cells were incubated with fAβ
(500 nmol/L) for an additional 18 h and were harvested for
detection of intracellular Aβ levels by Western blotting analysis.
The band intensity was measured in three independent exper-
iments indicating relative intracellular Aβ levels and the
mean ± SEM. are shown in the right panel. One-way ANOVA
with Turkey’s test, *P < 0.05; **P < 0.01; ***P < 0.001.
(B) Deacetylation of TFEB at K116 further stimulates lysosomal
biogenesis in microglia. Empty vector or GFP-tagged TFEB
(WT or K116R) was overexpressed in BV2 cells, followed by
staining with an antibody against LAMP1 (Red) or LysoTracker
Red, respectively. The ﬂuorescence signal of each cell was
estimated by examining more than 50 cells. One-way ANOVA
with Turkey’s test, *P < 0.05; **P < 0.01; ***P < 0.001. (C) Flow
cytometric analysis of lyososomes stained with LysoTracker
Red in BV2 cells treated as in (B). Values of mean ﬂuorescence
were expressed as fold changes. One-way ANOVA with
Turkey’s test, *P < 0.05; **P < 0.01. (D) Deacetylation status
at K116 further upregulates expression of TFEB target genes.
qPCR analysis of TFEB target genes in BV2 cells overex-
pressed with empty vector as control or TFEB (WT or K116R).
Values represent mean ± SEM of three independent experi-
ments. One-way ANOVA with Turkey’s test, comparison against
CTRL, *P < 0.05; **P < 0.01. (E) ChIP-qPCR analysis for TFEB
binding to its target gene CLCN7. The histogram shows the
amount of immunoprecipitated DNA as detected by qPCR
assay. Values were normalized to the input and displayed as
relative enrichment over a mock control. Values represent
mean ± SEM of three independent experiments. One-way
ANOVA with Turkey’s test, **P < 0.01; ***P < 0.001.
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BV2, HEK293T, and HeLa cell lines were obtained from Cell
Resource Center of Peking Union Medical College Hospital and
cultured in Dulbecco’s Modiﬁed Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) (Hyclone, USA) and
antibotics (100 U/mL penicillin, 100 µg/mL streptomycin). Cells
were incubated at 37°C in a 95% humidiﬁed atmosphere with 5%
CO2.
Primary microglia were prepared from the whole brains of 24-h-
old Sprague-Dawley (SD) rats as described previously (Ma et al.,
2013). Brieﬂy, pups were decapitated and then the meninges and
blood vessels were removed from the cortices which were minced
and digested with Dnase I (0.01%) and trypsin (0.25%) for 30 min at
37°C. The digestion was stopped by DMEM containing 10% FBS
and 1% penicillin-streptomycin. The cell mixture were then triturated
and plated on T75 ﬂask (Corning, USA). The media were changed to
fresh DMEM with 10% FBS 24 h later and were cultured for another
14–21 days at 37°C. Primary microglia were isolated by shaking the
plates for 2 h at 260 rpm. Cells were then counted and plated for
experiments at the appropriate density in DMEM/F12 containing 2%
FBS. The media were changed to serum-free DMEM/F12 overnight
before conducting the experiment. The enriched microglia
were >98% pure as determined by immunoﬂurescence shown with
Iba1-immunoreactive (IR) and GFAP-IR cells (Fig. S1C).
Preparation of ﬁbrillar Aβ
Human Aβ1–42 (20276; AnaSpec, USA) or Hilyte-Fluor-488 ﬁbrillar
Aβ1–42 (60479; AnaSpec, USA) were dissolved in 1 mmol/L phos-




































































































Figure 7. Microglial expression of deacetylated TFEB reduces amyloid plaques in the brain slices from APP/PS1 mice.
(A) Ex vivo degradation assay. BV2 microglia were infected with lentivirally overexpressed FugW3-TFEB (WT or K116R) and co-
cultured with 10 μm thick freshly cut, unﬁxed brain slices from aged APP/PS1 transgenic mice. After 48 h the slices were used for
subsequent analysis. (B–E) Deacetylation of TFEB at K116 further reduces amyloid plaques. BV2 microglia overexpressed with
vector control (CTRL) or TFEB (WTor K116R) were co-cultured with brain sections prepared as depicted in (A), followed by staining
amyloid plaques with thioﬂavine-S (Green) (B–D) or by Western blotting analysis of fAβ levels (E and F). CTX, cortex; HPC,
hippocampi. Results are mean area fraction of amyloid plaques ± SEM for 3 mice per group. The band intensity was measured in
three independent experiments indicating relative fAβ levels and the mean ± SEM. One-way ANOVA with Turkey’s test, *P < 0.05;
**P < 0.01. Scale bar, 200 μm.
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and stored at −20°C before use. The ultra structure of the peptide
aggregates was examined by transmission electron microscopy.
Plasmids and transfection
Human TFEB was subcloned into pCMV-Tag2B and pEGFP-N3,
respectively. Human SIRT1-WT and SIRT1-HY was subcloned into
pCMV-3×HA and pEGFP-N3, respectively. TFEB-K116R was
mutated from TFEB- pCMV-Tag2B and TFEB-pEGFP-N3, respec-
tively. Transient transfection of plasmids were conducted using
Lipofectamine LTX according to the instruction (Invitrogen), followed
by changing the medium 4 h later. The cells were harvested 24 h
later for the subsequent experiments.
Lentivirus infection
The FugW3 four-plasmid-lentivirus system were utilized to overex-
press SIRT1 (WT or HY) and TFEB (WT or K116R) in BV2 and
primary microglia. FugW3-GFP as a vector control and FugW3-
SIRT1-WT, -SIRT1-HY, -TFEB-WT, and -TFEB-K116R constructs
were transfected into 293T-packaging cells with three other helper
plasmids (RRE, REV, and VsVg) respectively, using Lipofectamine
LTX. Medium was changed 12 h later for another 60 h incubation
before collecting the supernatant which was ﬁltered through a
0.45 μm ﬁlter, aliquated and stored at −80°C. BV2 or primary
microglia was infected with the supernatant in the presence of 2 µg/mL
Polybrene for 24 h before changing the medium. Cells were harvested
48–72 h later for the subsequent experiments.
RNA interference
BV2 or primary microglia in 12-well plates were transfected with
siRNAs against target genes (SIRT1 siRNA: sc-40987; TFEB
siRNA: sc-38510; Santa Cruz Biotechnology, CA) or scramble
siRNA as control with Lipofectamine RNAiMAX (Invitrogen, Carls-
bad, CA). Cells were harvested 48–72 h later for the subsequent
experiments.
fAβ uptake and degradation
Measurements of fAβ uptake and degradation were performed as
depicted previously (Jiang et al., 2008). Brieﬂy, to measure local-
ization of the internalized fAβ, BV2 cells or primary microglia were


















fAβ degraded in lysosome
Lysosome
Figure 8. A schematic model of TFEB deacetylation on facilitating fAβ degradation in microglia by enhancing lysosomal
biogenesis. In the presence of fAβ stimulation, microglia take up fAβ and transport them into lysosomes. Meanwhile, TFEB
translocates into nucleus where it interacts with SIRT1 and is deacetylated at K116. Deacetylation of TFEB enhances its
transcriptional induction of its downstream target genes closely associated with lysomomal biogenesis, which eventually upregulates
microglial capability in degradation of fAβ.
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Aβ1–42 was added for 30 min. The cells were stained with Lyso-
Tracker Red before confocal imaging.
To analyse microglial degradation, 500 nmol/L in vitro synthetic
fAβ1–42 was incubated with BV2 and primary microglia for varying
times. Cells were infected with lentivirally overexpressed GFP,
SIRT1 (WT or HY), TFEB (WT or K116R) or were transfected with
siRNA for SIRT1 or TFEB for 72 h before incubation with 500 nmol/L
fAβ1–42 for another 3 h or 18 h, indicating microglial phagocytosis or
degradation of fAβ, respectively. Subsequently, cells were thor-
oughly washed with DMEM three times and lysed for Western
blotting Analysis. The band intensity was measured in three inde-
pendent experiments indicating relative intracellular fAβ levels.
Inhibitors for lysosome or NEP were added to the cells 2 h before
adding fAβ and were kept in the medium before harvest.
Antibodies and reagents
Mouse monoclonal anti-β-actin (ab3280; Abcam, MA); mouse
monoclonal anti-GAPDH (cw0266; CWBio; China); mouse mono-
clonal anti-HA (H9658; Sigma, St. Louis, MO); mouse monoclonal
anti-Flag M2 antibody (F3165; Sigma, St. Louis, MO); mouse mon-
oclonal anti-SIRT1 (8469; Cell Signaling Technology, MA); rabbit
polyclonal anti-SIRT1 (2493; Cell Signaling Technology, MA); goat
polyclonal anti-TFEB (ab2636; Abcam, MA); rabbit polyclonal anti-
TFEB (sc48784; Santa Cruz Biotechnology, CA); mouse monoclonal
anti-Aβ1–16 (6E10) (SIG39320, Covance, USA); rabbit monoclonal
acetylated-lysine antibody (9814; Cell Signaling Technology, MA);
rabbit polyclonal anti-Lamp1 (ab 24170; Abcam, MA); LysoTracker
Red (C1046; Beyotime, China); Leupeptin (L2884; Sigma, St. Louis,
MO); Chloroquine (C6628; Sigma, St. Louis, MO); Phosphoramidon
(R7385; Sigma, St. Louis, MO); Thioﬂavine-S (T1892; Sigma, St.
Louis, MO).
Western blotting analysis
Cells were harvested and lysed with lysis buffer consisting of
50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% NP-40, 1% SDS,
protease inhibitors cocktail (Sigma, St. Louis, MA) and 10% the
mixture of deoxyribonuclease I (1 mg/mL) and ribonuclease A
(0.25 mg/mL) at 4°C. The lysates were sonicated, followed by cen-
trifugation at 14,800 ×g at 4°C for 10 min to remove the insoluble
substances. The protein concentration was determined by 2-D
Quantitative Kit (GE Healthcare, USA). Equal amount the lysates
were resolved by 10% SDS-PAGE and transferred onto PVDF
membranes using a semi-dry blotting apparatus (Bio-Rad, USA).
After blocking with 5% non-fat milk in phosphate buffered saline
(PBS) with 0.05% Tween 20, the membranes were incubated
overnight at 4°C with primary antibodies, followed by incubation with
HRP-conjugated secondary antibodies (1031-05 or 4050-05;
Southern Biotech, MA). Protein bands were detected by chemilu-
minescence (Millipore, Billerica, MA).
Ex vivo degradation assay
Ex vivo degradation assays were performed as previous described
(Bard et al., 2000). Brieﬂy, 12-month-old APP/PS1 transgenic mice
were perfused with saline and cryostat sections (10 μm in thickness)
were cut from snap-frozened brain and mounted onto glass
coverslips pre-coated with poly-L-lysine. Brain sections were dried
for at least 2 h at room temperature and washed with hybridoma
serum-free media (H-SFM; Thermo Fisher) containing 1% FBS and
1% penicillin/streptomycin. BV2 microglia were seeded (8 × 105 cell/
mL) and co-cultured with the brain sections in 24-well plates for 48 h
at 37°C with 5% CO2. After incubation, sections were washed twice
with PBS and ﬁxed with 4% paraformaldehyde for subsequent
thioﬂavine-S staining or lysed in 6.25 mol/L guanidinhydrochloride
for Western blotting analysis.
Immunoprecipitation
Cells were pretreated with TSA (0.5 μmol/L) and NAM (10mmol/L), or
seperately. Then cells were harvested and lysed in ﬁve volume of lysis
buffer (25 mmol/LTris-HCl, 150 mmol/L NaCl, 3 mmol/L MgCl2, 0.5%
NP-40, 1 mmol/L DTT, 5% Glycerol, 1% PI, pH 7.5) for rotating at 4°C
for 2 h, followed by centrifugation at 21,000 ×g for 30 min. Then the
supernatant were mesured by 2-D Quantitative Kit. Equal amount of
protein was incubatedwith the ANTI-FLAGM2Afﬁnity Gel (Sigma, St.
Louis, MO) at 4°C overnight. Immunoprecipitates were washed with
lysis buffer for four times and eluted with SDS loading buffer, followed
by SDS-PAGE separation and Western blotting Analysis.
Mass spectrometry analysis
HEK293T cells were transfected with Flag-tagged TFEB for 24 h,
then the cells were pretreated with 0.5 μmol/L TSA and 10 mmol/L
NAM for 12 h before harvest. Cells were lysed and immunoprecipi-
tated as depicted above. The eluted mixture was resolved by 10%
SDS-PAGE and stained with Commassie Blue R250 and the bands
were excised from the gel, followed by tryptic digestion and mass
spectrometry. Modiﬁcation identiﬁcation was measured with the
database search accordingly and peptide identiﬁcations were vali-
dated with Proteome Discoverer 1.4.
In vitro deacetylation assay
Flag-tagged SIRT1 (WT or HY) and TFEB were puriﬁed from 293T
cells by immunoprecipitation. The deacetylation reaction was per-
formed in 100 μL of reaction buffer containing 5 μg of puridied Flag-
tagged TFEB proteins and 15 μg puriﬁed Flag-SIRT1-WT or SIRT1-
HY proteins in Tris-HCl buffer (Tris-HCl, PH 8.5, 50 mmol/L; NaCl
50 mmol/L; MgCl2 4 mmol/L; DTT 1 mmol/L; Glycerol 5%; NAD
+
5 mmol/L; NAM 10 mmol/L) at 30°C for 6 h. During the incubation,
the buffer was mixed every 5 min and the reaction was stopped by
SDS loading buffer, followed by SDS-PAGE separation and Western
blotting Analysis.
Immunoﬂuorescence
Cells were 4% PFA ﬁxed for 20 min, permeabilised in 0.1% PBST for
20 min, and then blocked in 10% BSA/0.05% PBST for 1 h at room
temperature. The cells were then incubated with primary antibody in
1% BSA/PBST overnight at 4°C, followed by a further incubation at
room temperature for 1 h with AlexaFluor secondary antibodies.
Images were acquired with LSM 710 NLO & DuoScan System
confocal laser-scanning microscope (Zeiss, Jena, Germany).
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Cells were incubated with LysoTracker Red (0.1 μmol/L) for 10 min
and washed by PBS thoroughly, followed by ﬂow cytometric analysis
on BD LSRFortessa instrument, 30,000 events per run. FlowJo
software was used to perform data analysis.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from cells with different treatments by Trizol
reagent (Invitrogen, USA), and 1 μg of total RNA was reverse
transcribed to cDNA using HiFi-MMLV cDNA ﬁrst strand synthesis
Kit (CW Bio, China). Quantitative PCR (qPCR) was carried out by
mixing cDNA with GoTaq qPCR Master Mix (Promega, USA) and the
reaction was performed on the CFX96 Real Time PCR Detection
system (Bio-Rad, USA), under the following conditions: 95°C, 2 min;
95°C, 15 s; 60°C, 30 s; 72°C, 25 s; followed by 40 cycles of 95°C,
15 s; 60°C, 2 min.
The primers for qPCR were designed according to gene
sequences published in theGenBank (SIRT1, forward, 5′-TGTGTC
ATAGGTTAGGTGGTGA-3′, reverse, 5′-AGCCAATTCTTTTTGTGT
TCGTG-3′; TFEB, forward, 5′-AAGGTTCGGGAGTATCTGTCTG-3′,
reverse, 5′-GGGTTGGAGCTGATATGTAGCA-3′; CTSA, forward, 5′-
TCCCAGCATGAACCTTCAGG-3′, reverse, 5′-AGTAGGCAAAGTA-
GACCAGGG-3′; CTSB, forward, 5′-ACAACGTGGACATGAGCTA
CT-3′, reverse, 5′-TCGGTAAACATAACTCTCTGGGG-3′; CTSD,
forward, 5′-TGCTCAAGAACTACATGGACGC-3′, reverse, 5′-CGAA
GACGACTGTGAAGCACT-3′; CTSF, forward, 5′-AGAGAGGCCCA
ATCTCCGT-3′, reverse, 5′-GCATGGTCAATGAGCCAAGG-3′;
VPS11, forward, 5′-CAAGCCTACAAACTACGGGTG-3′, reverse, 5′-
GAGTGCAGAGTGGATTGCCA-3′; VPS18, forward, 5′-CACTCGG
GGTATGTGAATGCC-3′, reverse, 5′-TCGGAAGGGGTGAAGTCAA
TG-3′; HEXA, forward, 5′-ACGTCCTTTACCCGAACAACT-3′,
reverse, 5′-CGAAAAGCAGGTCACGATAGC-3′; CLCN7, forward, 5′-
CCACGTTCACCCTGAATTTTGT-3′, reverse, 5′-AAACCTTCCGAA
GTTGATGAGG-3′; LAMP1, forward, 5′-CAGATGTGTTAGTGG-
CACCCA-3′, reverse, 5′-TTGGAAAGGTACGCCTGGATG-3′; LA
MP2, forward, 5′-GCACAGTGAGCACAAATGAGT-3′, reverse, 5′-
CAGTGGTGTGTATGGTGGGT-3′).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay (ChIP) was performed as
depicted previously (Hug et al., 2004). In brief, cells were transfected
with Flag-tagged TFEB-WTor TFEB-K116R for 24 h. The cells were
harvested for immunoprecipitation with ANTI-FLAG M2 Afﬁnity Gel
(Sigma, St. Louis, MO) and were then subjected to the ChIP assay
following the manufacturer’s instruction of Chromatin immunopre-
cipitation kit (9002, Cell Signaling Technology, MA). qPCR was
performed to ﬁgure out the TFEB binding in promoter. The data were
analysed and displayed as described previously (Settembre et al.,
2013a). Primer sequences of CLCN7 for amplifying puriﬁed DNA
were listed in the Table S1.
Statistical analysis
All functional experiments were repeated at least in three indepen-
dent experiments. The band intensity in Western blot analysis was
quantiﬁed by ImageJ. Data were analyzed by GraphPad Prism 5.0
software and shown by the mean ± SEM. Multiple sets of data were
analyzed by one-way or two-way ANOVA, and unpaired Student’s
t test was used to analyze two sets of data. Signiﬁcance level was
set at P < 0.05.
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